Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etodolac + lidocaine is a combination of two pharmaceutical agents commonly used for pain management. Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins involved in inflammation and pain[1][3][4][6]. It is primarily indicated for the treatment of mild to moderate pain, osteoarthritis, and rheumatoid arthritis[1][3][5]. Lidocaine is a local anesthetic that blocks sodium channels in neuronal cell membranes, preventing nerve impulse conduction and thereby providing local numbness or analgesia. The combination may be used topically or in compounded preparations to provide both anti-inflammatory effects from etodolac and local anesthesia from lidocaine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etodolac + lidocaine.